Biora Therapeutics (BIOR) Proxy Filing summary

Executive summary

• A special meeting of stockholders is scheduled for October 9, 2024, to address urgent corporate actions needed to maintain Nasdaq listing.

• The meeting will be held virtually to maximize shareholder participation and reduce costs.

• The Board recommends voting in favor of all proposals presented at the meeting.

Voting matters and shareholder proposals

• Stockholders will vote on a reverse stock split, a reduction in authorized shares, and potential adjournment to solicit more proxies.

• The reverse stock split aims to increase the per-share trading price to comply with Nasdaq's minimum bid price rule.

• The reduction in authorized shares is contingent on the reverse stock split and is designed to avoid an excessive number of unissued shares.

• Adjournment may be sought if there are insufficient votes to pass the proposals.

• No dissenter's or appraisal rights are available for these proposals.

Board of directors and corporate governance

• No director or officer has a substantial interest in the proposals beyond their status as shareholders.

• The Board retains discretion to determine the final reverse split ratio and whether to implement the proposals after shareholder approval.